Medical marijuana for the treatment of vismodegib-related muscle spasm.

Basal cell carcinoma (BCC) arises from loss-of-function mutations in tumor suppressor patched homologue 1, which normally inhibits smoothened homologue in the sonic hedgehog signaling pathway.1,2 Vismodegib, a smoothened homologue inhibitor,2 is US Food and Drug Administration (FDA) approved for metastatic or locally advanced BCC that has recurred after surgery or for patients who are not candidates for surgery and radiation.1,2 Common adverse effects of vismodegib are muscle spasms, alopecia, dysgeusia, nausea, and weight loss.